-
Mashup Score: 4PREEMPT CRC Study: Investigational Blood Test Is ‘Effective Option’ for CRC Screening | Cancer Nursing Today - 2 month(s) ago
An investigational blood-based test for colorectal cancer (CRC) “may provide a convenient and effective option” for CRC screening in the average-risk US population.
Source: www.cancernursingtoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3Bezuclastinib Plus Sunitinib Elicits Preliminary Activity, Is Safe in Pretreated GIST - 2 month(s) ago
The combination of bezuclastinib and sunitinib generated favorable efficacy outcomes vs historical data in patients with previously treated GIST.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
“Encouraging long-term safety and tolerability [was seen] with combination bezuclastinib and sunitinib therapy in part 1, with a median treatment duration of 32 weeks,” @JTrentMDPhD of @SylvesterCancer and coauthors wrote in a poster at @ASCO #GI25. https://t.co/gvEz9BoDL0
-
-
Mashup Score: 4Report from the 2025 ASCO Gastrointestinal Cancers Symposium - 3 month(s) ago
NEJM Group was on hand to cover the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held January 23 to 25 in San
Source: www.jwatch.orgCategories: General Medicine News, General HCPsTweet-
NEJM Group covered the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, held January 23 to 25 in San Francisco. Here, NEJM Journal Watch Oncology and Hematology Associate Editor Dr. @IlsonDavid reviews key trials. https://t.co/oXRBiNM5SD #GI25 https://t.co/UKekD1W2dt
-
-
Mashup Score: 5
At ASCO GI 2025, Boris Pasche, MD, PhD, of Karmanos Cancer Institute gave an overview of the TheraBionic P1 device and how it works as a systemic targeted therapy for advanced HCC.
Source: docwirenews.comCategories: General Medicine News, UrologyTweet-
🥄 At @ASCO #GI25, Boris Pasche, MD, PhD, of @karmanoscancer gave an overview of the TheraBionic P1 device and how it works as a systemic targeted therapy for advanced hepatocellular carcinoma. 📺 Learn more about how the device works: https://t.co/dbwDBbxgD3 https://t.co/H8PT6VcRZF
-
-
Mashup Score: 4Trastuzumab/Pertuzumab/Chemo Does Not Confer Response Advantage in Gastric/GEJ Cancer - 3 month(s) ago
Trastuzumab/pertuzumab/chemotherapy was associated with higher rates of toxicity and no mpRR improvement vs chemotherapy alone in HER2+ gastric cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Trastuzumab plus chemotherapy numerically improved PFS and OS vs chemotherapy alone in HER2-positive gastric and GEJ cancer, although this improvement was not observed following a protocol amendment that changed the chemotherapy backbone. @ASCO #GI25 https://t.co/WQqIcpnv3i https://t.co/JAWO8pU8tV
-
-
Mashup Score: 2
Tislelizumab plus irinotecan, paclitaxel, oxaliplatin, and 5-FU/leucovorin showcased encouraging efficacy and manageable safety in gastric/GEJ cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
“Tislelizumab plus POFI was well tolerated and showed preliminary antitumor activity in [patients with] advanced gastric cancer, [and] a phase 2 study at the recommended phase 2 dose [RP2D] is ongoing,” wrote Liyu Su of Fujian Cancer Hospital. @ASCO #GI25 https://t.co/DANieRiecx
-
-
Mashup Score: 2T-DM1 Shows Tolerability in HER2+ Biliary Tract Adenocarcinoma - 3 month(s) ago
T-DM1 was tolerable in HER2-positive biliary tract adenocarcinoma but did not significantly improve progression-free survival.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
In a phase 2 trial, T-DM1 was well-tolerated in HER2+ biliary tract adenocarcinoma, but it did not show a statistically significant improvement in PFS vs historical controls, according to findings presented at #GI25. https://t.co/SY2Us73hIJ
-
-
Mashup Score: 1
207Background: Checkpoint inhibitors (CPI) have been transformative for localized dMMR CRC (microsatellite instability-high [MSI-H]), but not for localized pMMR CRC (microsatellite stable [MSS]). The combination of BOT, a novel Fc-enhanced multifunctional …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
RT @pashtoonkasi: @ALBERTO87050566 #GI25 Just presented @ASCO👇🏽 https://t.co/Yfdac62rjJ @OncoAlert
-
-
Mashup Score: 3
Marwan G. Fakih, MD, explains the implications of the findings from the phase 2 trial of balstilimab plus botensilimab for the treatment of patients with microsatellite stable metastatic colorectal cancer without liver metastases.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Marwan G. Fakih, MD, explains the implications of the findings from the phase 2 trial of balstilimab plus botensilimab for the treatment of patients with microsatellite stable metastatic colorectal cancer without liver metastases. #GI25 | @cityofhope https://t.co/s3xs0jwr0k
-
-
Mashup Score: 1The Targeted Pulse: Sniffing out the Latest From ASCO GI 2025 and Fresh FDA Activity - 3 month(s) ago
Aspirin reduced recurrence by 50% in PIK3CA-mutated colorectal cancer, the DCISionRT test earned FDA breakthrough status for predicting radiotherapy benefit in DCIS, and nivolumab plus chemotherapy sustained efficacy in gastric/GEJ/esophageal cancers. We also provide an overview of key abstracts from ASCO GI and molecular oncology and how it is changing care.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
The Targeted Pulse: Sniffing out the Latest From ASCO GI 2025 and Fresh FDA Activity | #GI25 @karolinskainst @YJanjigianMD @ClinicaNavarra @VCSpecialists https://t.co/pH7AkPykM3
-
💡 An investigational blood-based test for colorectal cancer may be a "convenient and effective option” for screening in the average-risk US population, according to data presented at #GI25 by @AasmaShaukatMD of @nyugrossman and colleagues. ➡️ Read more: https://t.co/d3l987Yffs https://t.co/gk8vD5uj4j